INmune Bio, Inc.
INMB
$1.63
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.95% | -2.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.74% | -19.07% | |||
| Operating Income | 7.74% | 18.66% | |||
| Income Before Tax | 73.54% | -151.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 73.54% | -151.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 73.54% | -151.13% | |||
| EBIT | 7.74% | 18.66% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 76.81% | -142.50% | |||
| Normalized Basic EPS | 21.96% | 21.25% | |||
| EPS Diluted | 76.81% | -142.50% | |||
| Normalized Diluted EPS | 21.96% | 21.25% | |||
| Average Basic Shares Outstanding | 14.11% | 3.57% | |||
| Average Diluted Shares Outstanding | 14.11% | 3.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||